NCT03893019 is a EARLY_PHASE1 clinical trial of MB-CART20.1 in Melanoma (Skin), sponsored by Miltenyi Biomedicine GmbH.

Who is sponsoring NCT03893019?

NCT03893019 is sponsored by Miltenyi Biomedicine GmbH.

What drugs are being tested in NCT03893019?

Interventions in NCT03893019: MB-CART20.1.

What condition does NCT03893019 study?

NCT03893019 studies Melanoma (Skin).

Is NCT03893019 still recruiting?

NCT03893019 is currently terminated. Last updated 16 May 2024.

Last reviewed 2024-05-16 · How we verify

NCT03893019

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MB-CART20.1 Melanoma

Terminated EARLY_PHASE1 Last updated 16 May 2024

What this trial tests

EARLY_PHASE1 trial testing MB-CART20.1 in Melanoma (Skin) in 9 participants. Terminated before completion.

Timeline

8 March 2019

Primary endpoint
30 January 2023

30 January 2023

Quick facts

Lead sponsor	Miltenyi Biomedicine GmbH
Phase	EARLY_PHASE1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	9
Start date	8 March 2019
Primary completion	30 January 2023
Estimated completion	30 January 2023
Sites	1 location across Germany

Drugs / interventions tested

MB-CART20.1 — full drug profile →

Conditions studied

Melanoma (Skin) — all drugs for Melanoma (Skin) →

Sponsor

Miltenyi Biomedicine GmbH — full company profile →

Who can join

18 and older, any sex, with Melanoma (Skin). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase l multi-centric, single arm, prospective, open, dose-escalation study in patients with unresectable stage III oder IV melanoma. The trial will include 15 adult patients. The trial is a classic 3+3 design with 1 Log dose increments and maximum 3 dose levels of the intravenously administered MB-CART20.1.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

CAR T cells in solid tumors: challenges and opportunities.
Marofi F, Motavalli R, Safonov VA, Thangavelu L, et al · · 2021 · cited 394× · PMID 33494834 · DOI 10.1186/s13287-020-02128-1
Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany.
Albinger N, Hartmann J, Ullrich E. · · 2021 · cited 171× · PMID 33753909 · DOI 10.1038/s41434-021-00246-w
Molecular Markers and Targets in Melanoma.
Teixido C, Castillo P, Martinez-Vila C, Arance A, et al · · 2021 · cited 147× · PMID 34571969 · DOI 10.3390/cells10092320
Skin cancer: understanding the journey of transformation from conventional to advanced treatment approaches.
Hasan N, Nadaf A, Imran M, Jiba U, et al · · 2023 · cited 117× · PMID 37803407 · DOI 10.1186/s12943-023-01854-3
Cancer stem cell-targeted chimeric antigen receptor (CAR)-T cell therapy: Challenges and prospects.
Masoumi J, Jafarzadeh A, Abdolalizadeh J, Khan H, et al · · 2021 · cited 56× · PMID 34386318 · DOI 10.1016/j.apsb.2020.12.015
Chimeric Antigen Receptor (CAR) T Cell Therapy for Metastatic Melanoma: Challenges and Road Ahead.
Soltantoyeh T, Akbari B, Karimi A, Mahmoodi Chalbatani G, et al · · 2021 · cited 50× · PMID 34207884 · DOI 10.3390/cells10061450
CSPG4 as Target for CAR-T-Cell Therapy of Various Tumor Entities-Merits and Challenges.
Harrer DC, Dörrie J, Schaft N. · · 2019 · cited 50× · PMID 31779130 · DOI 10.3390/ijms20235942
The Current State of Treatment and Future Directions in Cutaneous Malignant Melanoma.
Ernst M, Giubellino A. · · 2022 · cited 49× · PMID 35453572 · DOI 10.3390/biomedicines10040822

Verify or expand the search:

Other trials of MB-CART20.1

Trials testing the same drug.

NCT06508775 — Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies · NA · recruiting
NCT03664635 — MB-CART20.1 Lymphoma · Phase 1, PHASE2 · completed

Other recruiting trials for Melanoma (Skin)

Currently open trials in the same condition.

NCT06643286 — Evaluation of a Personalised Survivorship Care Plan App for Patients With Melanoma · NA · recruiting
NCT06298734 — High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial · NA · recruiting
NCT05704647 — Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases · Phase 2 · recruiting
NCT05492682 — START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer · Phase 1 · active not recruiting
NCT05649683 — Immunological Functionnal Test Validation to Predict Melanoma Metastatic Patient Response to Checkpoint Inhibitors · NA · recruiting

Other Miltenyi Biomedicine GmbH trials

Trials by the same sponsor.

NCT06225050 — M-2018-334 in Hematological Malignancies · NA · not yet recruiting
NCT07178431 — MB-CART2019.1 in Refractory Multiple Sclerosis · Phase 1, PHASE2 · not yet recruiting
NCT07288879 — DALY II Japan/MB-CART2019.1 for DLBCL · Phase 2 · recruiting
NCT06508931 — Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric Patients With R/R B-Cell Neoplasms · Phase 2 · recruiting
NCT06189157 — MB-CART19.1 in Refractory SLE · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03893019 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Miltenyi Biomedicine GmbH
Last refreshed: 16 May 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03893019.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing